NeoGenomics, Inc. (NEO) Stock

NeoGenomics, Inc. operates an extensive network of laboratories dedicated to cancer-focused testing across the United States, Europe, and Asia. The company is structured into Clinical Services and Pharma Services segments, providing a wide array of testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers.

In its Clinical Services segment, NeoGenomics offers cytogenetics testing to study chromosomal abnormalities related to diseases, fluorescence in-situ hybridization for detecting specific DNA sequences, flow cytometry to analyze cell characteristics, and immunohistochemistry with digital imaging for protein localization in tissue samples. The company also provides molecular testing focusing on DNA and RNA analysis, as well as morphologic analysis conducted by pathologists to diagnose diseases.

Additionally, NeoGenomics supports pharmaceutical clients through its Pharma Services segment, offering comprehensive testing services for oncology programs from discovery through to commercialization. As a reference laboratory specializing in anatomic pathology, NeoGenomics plays a critical role in delivering precise diagnostic insights.

Founded in 2001 and headquartered in Fort Myers, Florida, NeoGenomics has established strategic alliances and laboratory service agreements with leading entities like Inivata Limited. The company's commitment to advancing cancer diagnostics and treatment through cutting-edge testing technologies underscores its leadership in the oncology testing market globally.